1349697-68-2

Upstream product

• 1349697-67-1 1,5-bis(benzyloxy)-2-(2-methylallyl)anthracene-9,10-dione 
• 1349697-69-3 (R)-1,5-bis(benzyloxy)-2-(2,3-dihydroxy-2-methylpropyl)anthracene-9,10-dione 
• 1349697-70-6 (R)-3-(1,5-bis(benzyloxy)-9,10-dioxo-9,10-dihydroanthracen-2-yl)-2-hydroxy-2-methylpropyl 4-methylbenzenesulfonate 
• 117-12-4 1,5-dihydroxyanthraquinone 
• 100-39-0 benzyl bromide 
• 157197-06-3 1-hydroxy-5-(2'-methylprop-2'-enyloxy)-9,10-anthraquinone 

Downstream Products

• 1349697-72-8 (R)-4-(1,5-bis(benzyloxy)-9,10-dioxo-9,10-dihydroanthracen-2-yl)-3-hydroxy-3-methylbutanoic acid 
• 1349697-71-7 (R)-1,5-bis(benzyloxy)-2-((2-methyl-4-oxooxetan-2-yl)methyl)anthracene-9,10-dione 
• 1447925-29-2 (R)-methyl 4-(1,5-bis(benzyloxy)-9,10-dioxo-9,10-dihydroanthracen-2-yl)-3-hydroxy-3-methylbutanoate 

Relevant academic research and scientific papers

Convergent de novo synthesis of vineomycinone B2 methyl ester

An efficient de novo synthesis of vineomycinone B2 methyl ester has been achieved. The longest linear route required only 14 steps from achiral commercially available starting materials (4.0% overall yield). The key transformations included the de novo asymmetric synthesis of two key fragments, which were joined by a convergent late stage Suzuki's glycosylation for the construction of the aryl β-C-glycoside. A subsequent BBr3 one-pot debenzylation, demethylation and air oxidation provided vineomycinone B2 methyl ester.

De novo asymmetric synthesis of fridamycin e

A de novo asymmetric synthesis of (R)- and (S)-fridamycin E has been achieved. The entirely linear route required only nine steps from commercially available starting materials (16% overall yield). Key transformations included a Claisen rearrangement, a S